Search

Displaying results 4031 - 4040 of 6074 in total
  1. Drug

    Epratuzumab

    go.drugbank.com/drugs/DB04958
    Investigational

    This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.

  2. Drug

    RTP-801i

    go.drugbank.com/drugs/DB06048
    Investigational

    The proposed primary indication for RTP-801i is the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD or ARMD).

  3. Drug

    VLTS-934

    go.drugbank.com/drugs/DB05597
    Investigational

    VLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD).

  4. Drug

    Calcitonin gene-related peptide

    go.drugbank.com/drugs/DB06379
    Investigational

    A 37-amino acid peptide derived from the calcitonin gene. It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in the brain, gut, perivascular nerves, and other tissue. ...

  5. Drug

    BLX-883

    go.drugbank.com/drugs/DB05904
    Investigational

    BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C.

  6. Drug

    Flunixin

    go.drugbank.com/drugs/DB11518
    ExperimentalVet approved

    Flunixin is a non-steroidal anti-inflammatory drug for use in pigs, cattle and horses. It exerts analgesic and antipyretic effects. This drug is often prepared for use in meglumine salt form.

  7. Drug

    Alvocidib

    go.drugbank.com/drugs/DB03496
    Investigational

    Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer.

  8. Drug

    KD7040

    go.drugbank.com/drugs/DB05214
    Investigational

    KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07.

  9. Drug

    Rivoglitazone

    go.drugbank.com/drugs/DB09200
    Investigational

    Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.

  10. Drug

    OS2966

    go.drugbank.com/drugs/DB17207
    Investigational

    OS2966 is a humanized integrin β1 (CD29) blocking antibody currently evaluated for the treatment of acute myeloid leukemia, glioblastoma and ovarian cancer.[A254561, L47351]